About UCB

UCB aspires to be the patient-centric global biopharmaceutical leader transforming the lives of people living with severe diseases.

By integrating biology (bio) and chemistry (pharma), we can gain much deeper insights into disease pathways, including the complexities of severe diseases, as well as producing more potent, cost-effective drugs.

The unique combination of expertise in large, antibody-based molecules and small, chemically-derived molecules places us in a strong position to realise this ambition.
Cimzia®, our New Biological Entity (NBE), targeted at Crohn’s disease and rheumatoid arthritis, is one of the first fruits of this synergy of biology and chemistry.

In a knowledge- and ideas-based industry like ours, human capital is the lifeblood of success. To unlock the creative potential of our global team of more than 8,000 staff and our partners, we are creating a networked, cross-functional organisation.

Multi-disciplinary teams are working on all development projects, including members of R&D, supply chain and sales, as well as partners and patients…
UCB People, an innovative intranet tool, links our knowledge and skills. Our virtual R&D collaboration platform, based on the principles of Wikipedia, is another example.

Back to Who We Are

Back to Study Sponsor and Funding Partners